目的 探討舍曲林聯(lián)合尼莫地平對急性缺血性卒中患者血管性認(rèn)知功能損害的影響。方法 選取2015年11月—2017年11月在佛山市第二人民醫(yī)院就診的68例急性缺血性卒中血管性認(rèn)知功能損害患者，隨機(jī)分為觀察組和對照組，每組各34例。對照組在常規(guī)治療基礎(chǔ)上給予患者口服尼莫地平30 mg，3次/d。觀察組在對照組基礎(chǔ)上給予患者口服舍曲林50 mg，每晚1次。兩組均治療4周。對比兩組簡易精神狀態(tài)檢查量表（MMSE）、蒙特利爾認(rèn)知評(píng)估量表（MoCA）、阿爾茨海默病評(píng)定量表認(rèn)知部分量表（ADAS-cog）、美國國立衛(wèi)生研究院腦卒中量表（NIHSS）、日常生活能力評(píng)定量表（BI指數(shù)）評(píng)分和不良反應(yīng)發(fā)生情況。結(jié)果 治療前兩組MMSE評(píng)分、MoCA評(píng)分、ADAS-cog評(píng)分、NIHSS評(píng)分和BI指數(shù)比較，差異無統(tǒng)計(jì)學(xué)意義。治療后兩組MMSE評(píng)分、MoCA評(píng)分和BI指數(shù)均顯著高于治療前，ADAS-cog評(píng)分和NIHSS評(píng)分均顯著低于治療前，同組治療前后比較差異均有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組MMSE評(píng)分、MoCA評(píng)分和BI指數(shù)均顯著高于對照組，ADAS-cog評(píng)分和NIHSS評(píng)分均顯著低于對照組，組間差異均有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組不良反應(yīng)發(fā)生率8.82%（3/34），與對照組不良反應(yīng)發(fā)生率5.88%（2/34）比較，差異無統(tǒng)計(jì)學(xué)意義。結(jié)論 舍曲林聯(lián)合尼莫地平可有效減輕急性缺血性卒中患者血管性認(rèn)知功能損害，值得臨床推廣。

Objective To investigate the effect of sertraline on vascular cognitive impairment (VCI) in patients with acute ischemic stroke.Methods 68 patients with acute ischemic stroke VCI in our hospital from November 2017 to November 2015 were randomly divided into the observation group (nimodipine + sertraline, n=34) and the control group (nimodipine, n=34). The MMSE score, MoCA score, ADAS-cog score, NIHSS score, BI index and incidence of adverse reactions were compared between the two groups. Results There was no significant difference in the scores of MMSE, MoCA, ADAS-cog, NIHSS and BI between the two groups before treatment. After treatment, the MMSE score, MoCA score and BI index of the two groups were significantly higher than those before the treatment (P<0.05), and the ADAS-cog score and the NIHSS score were significantly lower than those before the treatment (P<0.05), and the MMSE score, MoCA score and BI index in the observation group were significantly higher than those in the control group (P<0.05), the ADAS-cog score and NIHSS score in the observation group were significantly lower than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was 8.82% (3/34), and the incidence of adverse reactions in the control group was 5.88% (2/34). There was no significant difference between the two groups.Conclusion Sertraline can effectively improve VCI in patients with acute ischemic stroke, and is worthy of clinical promotion.